Skip to main content

Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.

Publication ,  Journal Article
Lessin, SR; Duvic, M; Guitart, J; Pandya, AG; Strober, BE; Olsen, EA; Hull, CM; Knobler, EH; Rook, AH; Kim, EJ; Naylor, MF; Adelson, DM ...
Published in: JAMA Dermatol
January 2013

OBJECTIVE: To evaluate the efficacy and safety of a novel mechlorethamine hydrochloride, 0.02%, gel in mycosis fungoides. DESIGN Randomized, controlled, observer-blinded, multicenter trial comparing mechlorethamine, 0.02%, gel with mechlorethamine, 0.02%, compounded ointment. Mechlorethamine was applied once daily for up to 12 months. Tumor response and adverse events were assessed every month between months 1 and 6 and every 2 months between months 7 and 12. Serum drug levels were evaluated in a subset of patients. SETTING: Academic medical or cancer centers. PATIENTS: In total, 260 patients with stage IA to IIA mycosis fungoides who had not used topical mechlorethamine within 2 years and were naive to prior use of topical carmustine therapy. MAIN OUTCOME MEASURES: Response rates of all the patients based on a primary clinical end point (Composite Assessment of Index Lesion Severity) and secondary clinical end points (Modified Severity-Weighted Assessment Tool and time-to-response analyses). RESULTS: Response rates for mechlorethamine gel vs ointment were 58.5% vs 47.7% by the Composite Assessment of Index Lesion Severity and 46.9% vs 46.2% by the Modified Severity-Weighted Assessment Tool. By the Composite Assessment of Index Lesion Severity, the ratio of gel response rate to ointment response rate was 1.23 (95% CI, 0.97-1.55), which met the prespecified criterion for noninferiority. Time-to-response analyses demonstrated superiority of mechlorethamine gel to ointment (P< .01). No drug-related serious adverse events were seen. Approximately 20.3% of enrolled patients in the gel treatment arm and 17.3% of enrolled patients in the ointment treatment arm withdrew because of drug-related skin irritation. No systemic absorption of the study medication was detected. CONCLUSION: The use of a novel mechlorethamine, 0.02%, gel in the treatment of patients with mycosis fungoides is effective and safe. TRIAL REGISTRATION: clinicaltrials.gov Identifier:NCT00168064.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAMA Dermatol

DOI

EISSN

2168-6084

Publication Date

January 2013

Volume

149

Issue

1

Start / End Page

25 / 32

Location

United States

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Time Factors
  • Skin Neoplasms
  • Single-Blind Method
  • Severity of Illness Index
  • Ointments
  • Neoplasm Staging
  • Mycosis Fungoides
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lessin, S. R., Duvic, M., Guitart, J., Pandya, A. G., Strober, B. E., Olsen, E. A., … Kim, Y. H. (2013). Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol, 149(1), 25–32. https://doi.org/10.1001/2013.jamadermatol.541
Lessin, Stuart R., Madeleine Duvic, Joan Guitart, Amit G. Pandya, Bruce E. Strober, Elise A. Olsen, Christopher M. Hull, et al. “Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.JAMA Dermatol 149, no. 1 (January 2013): 25–32. https://doi.org/10.1001/2013.jamadermatol.541.
Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, Hull CM, Knobler EH, Rook AH, Kim EJ, Naylor MF, Adelson DM, Kimball AB, Wood GS, Sundram U, Wu H, Kim YH. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013 Jan;149(1):25–32.

Published In

JAMA Dermatol

DOI

EISSN

2168-6084

Publication Date

January 2013

Volume

149

Issue

1

Start / End Page

25 / 32

Location

United States

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Time Factors
  • Skin Neoplasms
  • Single-Blind Method
  • Severity of Illness Index
  • Ointments
  • Neoplasm Staging
  • Mycosis Fungoides
  • Middle Aged